Impact of a biomarker-based strategy on oncology drug development : a meta-analysis of clinical trials leading to FDA approval

Impact of a biomarker-based strategy on oncology drug development : a meta-analysis of clinical trials leading to FDA approval

Denis L. Fontes Jardim, Maria Schwaederle, Caimiao Wei, J. Jack Lee, David S. Hong, Alexander M. Eggermont, Richard L. Schilsky, John Mendelsohn, Vladimir Lazar, Razelle Kurzrock

ARTIGO

Inglês

In order to ascertain the impact of a biomarker-based (personalized) strategy, we compared outcomes between US Food and Drug Administration (FDA)-approved cancer treatments that were studied with and without such a selection rationale. Anticancer agents newly approved (September 1998 to June 2013)...

Fechado

Impact of a biomarker-based strategy on oncology drug development : a meta-analysis of clinical trials leading to FDA approval

Denis L. Fontes Jardim, Maria Schwaederle, Caimiao Wei, J. Jack Lee, David S. Hong, Alexander M. Eggermont, Richard L. Schilsky, John Mendelsohn, Vladimir Lazar, Razelle Kurzrock


										

Impact of a biomarker-based strategy on oncology drug development : a meta-analysis of clinical trials leading to FDA approval

Denis L. Fontes Jardim, Maria Schwaederle, Caimiao Wei, J. Jack Lee, David S. Hong, Alexander M. Eggermont, Richard L. Schilsky, John Mendelsohn, Vladimir Lazar, Razelle Kurzrock

    Fontes

    Journal of the national cancer institute

    Vol. 107, no. 11 (Nov., 2015), n. art. djv253